<SEC-DOCUMENT>0001144204-14-020779.txt : 20140404
<SEC-HEADER>0001144204-14-020779.hdr.sgml : 20140404
<ACCEPTANCE-DATETIME>20140404140232
ACCESSION NUMBER:		0001144204-14-020779
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20140402
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20140404
DATE AS OF CHANGE:		20140404

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cellectar Biosciences, Inc.
		CENTRAL INDEX KEY:			0001279704
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				043321804
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	333-119366
		FILM NUMBER:		14745381

	BUSINESS ADDRESS:	
		STREET 1:		3301 AGRICULTURE DRIVE
		CITY:			MADISON
		STATE:			WI
		ZIP:			53716
		BUSINESS PHONE:		617-244-1616

	MAIL ADDRESS:	
		STREET 1:		3301 AGRICULTURE DRIVE
		CITY:			MADISON
		STATE:			WI
		ZIP:			53716

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NOVELOS THERAPEUTICS, INC.
		DATE OF NAME CHANGE:	20050617

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	COMMON HORIZONS INC
		DATE OF NAME CHANGE:	20040211
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>v373983_8k.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B><BR>
<B>SECURITIES AND EXCHANGE COMMISSION</B><BR>
Washington, D.C. 20549</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report: April 2, 2014<BR>
(<I>Date of earliest event reported</I>)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CELLECTAR BIOSCIENCES, INC.</B><BR>
(<I>Exact name of registrant as specified in its charter</I>)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 30%; padding: 0; text-indent: 0; border-bottom: Black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Delaware</B></P></TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 30%; padding: 0; text-indent: 0; border-bottom: Black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>333-119366</B></P></TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 30%; padding: 0; text-indent: 0; border-bottom: Black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>04-3321804</B></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(State or other jurisdiction</I></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>of incorporation)</I></P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Commission</I></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>File Number)</I></P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(IRS Employer</I></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Identification Number)</I></P></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>3301 Agriculture Drive </B><BR>
<B>Madison, WI 53716</B><BR>
(<I>Address of principal executive offices</I>)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(608) 441-8120</B><BR>
(<I>Registrant&rsquo;s telephone number, including area code</I>)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD>Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD>Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD>Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD>Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 1in; text-align: left"><B>ITEM 7.01</B></TD><TD><B>REGULATION FD DISCLOSURE</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 2, 2014, we issued a press release
announcing that Dr. Simon Pedder had become President and Chief Executive Officer on April 1, 2014, following six months as Acting
Chief Executive Officer. A copy of the press release is furnished as Exhibit 99.1 and is incorporated by reference in this Item.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 1in; text-align: left"><B>ITEM 9.01</B></TD><TD><B>FINANCIAL STATEMENTS AND EXHIBITS</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(d) Exhibits</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 20%; border-bottom: black 1pt solid; padding: 0; font-size: 10pt; text-align: center; text-indent: 0"><FONT STYLE="font-size: 10pt">Number</FONT></TD>
    <TD STYLE="width: 2%; font-size: 10pt; text-align: center; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 78%; border-bottom: black 1pt solid; padding: 0; font-size: 10pt; text-indent: 0"><FONT STYLE="font-size: 10pt">Title</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: center; padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">Press Release dated April 2, 2014 entitled &ldquo;Dr. Simon Pedder Becomes Chief Executive Officer of Cellectar Biosciences&rdquo;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SIGNATURE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR>
    <TD STYLE="vertical-align: top">Dated: April 4, 2014</TD>
    <TD COLSPAN="2"><B>CELLECTAR BIOSCIENCES, INC.</B></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; width: 50%">&nbsp;</TD>
    <TD STYLE="width: 4%">By:&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 46%">/s/ Joanne M. Protano</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-top: #000000 1px solid">Name:&nbsp;Joanne M. Protano<BR>Title:&nbsp;&nbsp;&nbsp;Vice President and Chief Financial Officer</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 20%; border-bottom: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">Number</FONT></TD>
    <TD STYLE="width: 2%; font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 78%; border-bottom: black 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt">Title</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Press Release dated April 2, 2014 entitled &ldquo;Dr. Simon Pedder Becomes Chief Executive Officer of Cellectar Biosciences&rdquo;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>v373983_ex99-1.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><img src="logo.jpg"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center; text-indent: 0in"><B>Dr. Simon
Pedder Becomes President and Chief Executive Officer of Cellectar Biosciences</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>MADISON, Wis., April 2, 2014,</B> &ndash;
Cellectar Biosciences, Inc. (OTCQX: CLRB), a clinical stage biopharmaceutical company developing innovative agents for the detection
and treatment of cancer,<B> </B>announced that effective April 1, 2014, Dr. Simon Pedder transitioned to President and CEO of Cellectar
as planned following six months as acting chief executive officer. Dr. Pedder will continue to serve as a director.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;Under Simon&rsquo;s leadership,
Cellectar has already made measurable progress in focusing the company&rsquo;s development programs, initiating its first Phase
II trial and mapping a path toward initial approval of our product candidates,&rdquo; said Dr. Stephen Hill, Chairman of the Board.
&ldquo;The Board of Directors looks forward to his continued contributions as we work toward advancing our pipeline of promising
cancer-targeting agents while optimizing our internal resources and increasing shareholder value.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;I believe Cellectar&rsquo;s
highly selective cancer-targeting platform technology has the potential to radically change the way a broad range of cancers are
detected, treated and monitored,&rdquo; commented Dr. Pedder. &ldquo;The challenges that lay before us are to successfully identify
the most efficient and risk-mitigating strategies for validating our core technology and prioritizing those indications in which
there are significant unmet clinical needs, well-defined regulatory paths and viable commercial markets. Given the shared core
platform of our agents, our initial development opportunities should provide a strong foundation from which to expand into additional
addressable markets. I am pleased by the progress towards these goals to date, appreciative of the support expressed by shareholders
and investigators during this transition and look forward to solid operational execution driving delivery of near-term trial data
and long-term success.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dr. Pedder was named acting chief executive
officer and elected a director of Cellectar in October 2013. He has been involved in four successful new drug applications and
his expertise spans many areas, including clinical development, orphan drug development, licensing and public company financing.
Prior to joining Cellectar, Dr. Pedder held senior leadership positions at Hoffmann La Roche, including serving as an Officer and
Vice President of Pharma Business Oncology. Following his tenure at Roche, Dr. Pedder founded and served as president and chief
executive officer of Chelsea Therapeutics, a Charlotte-based public biopharmaceutical company that acquires and develops innovative
products for the treatment of a variety of human diseases, including central nervous system disorders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About Cellectar Biosciences, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cellectar Biosciences is developing agents
to detect, treat and monitor a broad spectrum of cancers. Using a novel phospholipid ether analog (PLE) platform technology as
a targeted delivery and retention vehicle, Cellectar&rsquo;s compounds are designed to be selectively taken up and retained in
cancer cells including cancer stem cells. With the ability to attach both imaging and therapeutic agents to its proprietary delivery
platform, Cellectar has developed a portfolio of product candidates engineered to leverage the unique characteristics of cancer
cells to &ldquo;find, treat and follow&rdquo; malignancies in a highly selective way. I-124-CLR1404 is a small-molecule, broad-spectrum,
cancer-targeted PET imaging agent currently being evaluated in a Phase II glioblastoma imaging trial. Additionally, multiple investigator-sponsored
Phase I/II clinical trials are ongoing across 11 solid tumor indications. I-131-CLR1404 is a small-molecule, broad-spectrum, cancer-targeted
molecular radiotherapeutic that delivers cytotoxic radiation directly and selectively to cancer cells including cancer stem cells.
A Phase Ib dose-escalation trial of I-131-CLR1404 in patients with advanced solid tumors was completed in the first quarter of
2014 and results have been submitted to the American Society of Clinical Oncology (ASCO) 2014 Annual Meeting. CLR1502 is a preclinical,
cancer-targeted, non-radioactive optical imaging agent for intraoperative tumor margin illumination and non-invasive tumor imaging.
For additional information please visit www.cellectar.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>INVESTOR CONTACT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Kate McNeil, Vice President of IR, PR &amp; Corporate Communications</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Cellectar Biosciences, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Phone: (347) 204-4226</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Email: kmcneil@cellectar.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This news release contains forward-looking
statements.&nbsp; You can identify these statements by our use of words such as &ldquo;may,&rdquo; &ldquo;expect,&rdquo; &ldquo;believe,&rdquo;
&ldquo;anticipate,&rdquo; &ldquo;intend,&rdquo; &ldquo;could,&rdquo; &ldquo;estimate,&rdquo; &ldquo;continue,&rdquo; &ldquo;plans,&rdquo; or
their negatives or cognates.&nbsp;&nbsp; These statements are only estimates and predictions and are subject to known and unknown
risks and uncertainties that may cause actual future experience and results to differ materially from the statements made.&nbsp;
These statements are based on our current beliefs and expectations as to such future outcomes.&nbsp; Drug discovery and development
involve a high degree of risk.&nbsp; Factors that might cause such a material difference include, among others, uncertainties related
to the ability to raise additional capital, uncertainties related to the ability to attract and retain partners for our technologies,
the identification of lead compounds, the successful preclinical development thereof, the completion of clinical trials, the FDA
review process and other government regulation, our&nbsp;pharmaceutical collaborators&rsquo; ability to successfully develop and commercialize
drug candidates, competition from other pharmaceutical companies, product pricing and third-party reimbursement. A complete description
of risks and uncertainties related to our business is contained in our periodic reports filed with the Securities and Exchange
Commission including our Form 10-K for the year ended December 31, 2013. These forward-looking statements are made only as of the
date hereof, and we disclaim any obligation to update any such forward-looking statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``(!`0(!`0("`@("`@("`P4#`P,#
M`P8$!`,%!P8'!P<&!P<("0L)"`@*"`<'"@T*"@L,#`P,!PD.#PT,#@L,#`S_
MVP!#`0("`@,#`P8#`P8,"`<(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`S_P``1"`!*`1<#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#]^QPQ`Z4C
M$=P,TI;CCFO._P!IK]ISP9^R)\)=0\:^.M7CTG1K#"*`-]Q>3$'9!!&.9)6(
MX4>A)(4$ATJ4ZLU3IIMO1);MB;L>AAN>`*\Z^)7[6WPP^#FOVND^)_'WA+1-
M7OKB.T@L+K5(4NY99&"(@AW;R2Q`''>OQ"_;G_X+C_%G]K#4KW2O"U]>?#7P
M*Y,<=CIEP4U*]CY&;FZ7Y@2#S'$54="7ZU\L?`(A_P!HGP)/*QDFE\4:8TDK
MG<[DWD7)8\D^YK])P'AS7=!U\;4Y+*_*M7\WM]USFEB5>T4?U5#D#)&#7YY_
M\'$/[6'C+]FG]G7P39>!?$^L>%-<\3:[(9+S3)_(N6M[>W9VC#CD`R/#G'7&
M#P2#^A>1P?2OS_\`^"PW[&%Y^VK\;/A-IL6O1Z;:^'Y&:2UDB+B?[1<P*YR.
MAV0D?C7P>4YA@,#C*=?,6E33UNKJ[325K/=V-:\N6#9]J?`^769O@UX2D\07
M+7>O/HMFVI3L@0S7)@3S7(&`"7W'`&!FMCQ=XNTSP)X9U#6M;O[32](TJ![J
M[N[J410VT2#<SNQX"@`G)H\6>*])^'GA*^UG6;ZUTK1M(MFN;JZN)!'#;0HN
M69B>``!7XV_M.?M1_$O_`(+I_M#I\(/@_!=:/\)]*G6XO[^X1XXKN)7P+Z]Q
MR(\@F&V^\[`,W(_=]F593+,*LZC:A2CK*3V2[+S[(<ZEE;=GWC^PI_P5N\)?
MM]?M`^-_!7A/PUK]OIWA6U%[::Y<;3;:I#YHBW%``T!9CN17R70,?E*E:^MA
MA@<<9KQ[]BS]BWP9^PQ\&;3P?X.M&W$B?4M3G4&\UBYQAIYF'?LJCY47``QU
M]AP%]R:XLSEA98B7U.+5-62N[MVZOM?>W0J'-;WMQ:***XB@HHHH`****`"B
MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@#-\3>)+#P
M9X<U#6-5NX;#3-+MI+N[N9FVQV\,:EW=CV"J"2?05_.!_P`%+/V_];_X*!_M
M!W>O2S7=MX+T5Y+7POI3$JEK;9P;AUZ>?-@,Q/*C:@X7G]4/^#B;]HZX^#_[
M$]OX/TZ=H-0^)NIKIDI4X;[#"OG7(SZ-B*,^JRD5^(/PW^'NK?%SXB:!X3T*
M'[3K?B;48-+L8ST:::0(I/\`L@G)/8`U^N>'F3TJ=&6:5UW46^B6[^>WR?<X
ML3-M\B/8_P!@/_@G7X[_`."A'Q'FTKPTL>E>'M*9?[:\0W<9:UTX$9$:J,&6
M=ARL8(XY8JO)_:O]E'_@C+\"?V58=/NX?"T'C#Q/8LDQUSQ$JWLXE7!#Q1$>
M5#AAE=B`CCYB1FO8OV1?V7?#O['/[/\`X>\`>&H46ST:`?:+G8%EU&Y89FN9
M/5Y'R?884<*!7;^,?&FF^`]&DU#5+N.TMH^-S<LS=E4#EB?05\CQ3QMB,7.?
M+4Y*,;];77>3\^VQK3I1@KR-8CG@=*\F\??":ZN_C5I_C"^U"QM]#TF)9)?-
M8J\7EACZ8P6(.<COQ58?MG>&FO3&UEK(ASCSO)0CZXW9Q^M'Q;\.:G^T-IFB
MOX8U>SD\/2N?M@+%2K@C#,N,L5&?D.,'!]Q^09GF>"S##M85^VG!J2BG9MIZ
M-]TGN*=2$H^[JUT/+_C_`&>H_MXV>I>!-,5[3PU<+^]F=3MX/$TH[C(RL?<\
MGG[OK/['_P"QOX*_8D^$%OX1\%V`MX"_VB_OI1NN]4N"/FFF?N>P7[JJ`H``
MI_B?P/K_`,*/`5AIWP]M(I;AYO\`39I-C3/E>9#O(4DG\AC`Q7A'[5_[(_QW
M_:C^#UYX?TWX@2>#=0NY4<W(U*:W`0'YE(M0"01VSBNO(<=C*%99?C93?M9*
M4FE^[C=:6UU27XD04H2NTVW]Q]8>*OB5X=\#-"NMZ_HVCO<NL<0O;Z*W,K,<
M*J[V&23P`.M;O7@C.*_*;P-_P;#Z5K-Y%>_$?XOZ]K]P[!KB/3M/6%Y!GD>?
M.\K\^NT&OU.T?2HM$TFUL8`_DV<*0Q[V+MM50HR3R3@=3UK[G-,)@J/*L)6=
M1ZW]UQ2VM:[UZG3"4G\2L7`V>HQFE!':O%_CM^W;X!^`OC6'PG<SZUXH\<7,
M:SQ^&?#.F2ZOJPC/21XH@1"A[-*R`]LUR=Q_P4BL_#<1O/%7P?\`CKX2T9?F
MDU2\\*_:K:V3^_*+26:1%'?*<=ZY88&O)*2B]=O/T[E-GTH"3U&*.:YKX6?%
MKPW\;?`]AXF\(ZYIOB'0-33?;7UE,)891G!&1T8'@J<$$$$`UTG08SC-<LHR
MBW%JS708M%&X>HHSGI3`**,YZ<T4`%%&0.I%%`!111N`ZD4`%%&X>HHH`**@
MO;^#38#+<3PP1KU>1PBC\33K:ZCO(5EBD26-QE61@RM]"*=G:X$M%&<=>*-P
M]12`**,CU%%`!11G/3FB@`HHW#U%&X>HH`****`/QI_X.?O$5Q/\:OA)I)=A
M:VNBZA>*N>-\D\*$_7$8KYV_X(5>#[7QA_P4\\`"\194TBVU'4XU;IYL=I(J
M'Z@R9_"OJG_@Z"^&\RWWP@\91QLUN1J&ASL!PCGRIX@3[A9O^^37Q'_P2@^-
MMK^S]_P4+^&/B#4)DM]-N=1;1KR60[4BCO(GM@['L%DDC)/8"OW+)4ZO"CA2
MWY)KYW9P5':KKW1_2B`#@CH*^5OVN/$]SK/Q4?3G=C:Z5"BQ1_P[G`=G^I!`
M^@KZIXP,\"O!?VJO@I?ZWJ">)-)MY+R18Q%>6\8W2$#[LBC^+`X('.`#ZU_+
M/'6%Q-?*Y1PR;LTY);M*_P"3L_D:XN,G3]T^?J]9_8]\3SZ9\2)]+#N;34[=
MW=/X1)'@A_K@D?EZ5Y0()&N!"(Y3,3CRPAWY],=<U]$_LJ_!6^\+SS^(=8MY
M+6XGB\FU@D&)$0D%G8?PDX``/.,YZU^5\'8+%5,UISHII1=Y/HEUOZK0\["0
MDZB:Z'M[')&":^8_VA?^"O'P*_9;^+NJ>!?&GB?4=-\1Z*L+75O%HMW<*@EB
M65,/'&5.4=3P>,XKZ;R`23Q7\R__``4C^-=M^T/^W=\4?%EC.MSIMYK;VEC,
MO*RV]LBVT;CV80[A[-7]:\'</TLUQ,Z==M1C&]UIJVK;I^9ZE:JX)6/WW_9)
M_P""B7PI_;BU?7+'X<Z[>ZO=>'889[Y9],N+,1)*SJA!E10V2C=,XQ7;?M0?
M%>7X$?LX^//&L$2W%QX4T"]U6&-AE9)(8'D12/0LHS[5^<?_``:^?#J>T\$?
M%OQ?+$X@U'4;#2+>0CAS!%)+(!]/M$=?IY\2?`6G?%;X=Z[X7U9&ETOQ%I\^
MF7:`X+131M&X'OM8UP9[@L-@,TEAJ3<H0:O??9-[+U1=.3E&[/'_`/@G5^S[
MI_P3_9LT+4YB-4\9^.K2'Q%XKUZ<;[S6M0N8Q-(\DAY*(7V(N=JHH``YS[X,
M^@.:^-?V=_VME_8E\):5\(_V@)YO"M[X3C72M"\9W4+C0/%5C$`EO)]J`*07
M(B"K)%*5.Y206#5ZUXN_X*3_``#\$:2;V]^+W@*:,C*16.L0WUQ,>P2&`O(Y
M/8*I)KCQF$Q-2NY).7,[II-IKRMY=.A7,K'I'P^^#'A;X2ZCKUUX9T'3M#F\
M3WQU/5#91");VY*!#,RCY=Y"C)`&3R<G)KXP_;,TWX3^)/\`@IM9:?\`&CQ%
M::'X3B^&<5Q8B^\33Z);/>_VI,N0T<T6]_*W<$G@=.*^JOV8?C]J?[1_A/4/
M$,_@?Q'X+T5KTQ:*=<58+S6+0*I%V;?[]NK,6"I)\Q4!L#.*^:OVD_BW\+_@
M[_P55AU#XL:EX;TS0[OX5Q6]I)K4*RP/<?VM*VU0RL`^P,?IFMLO5:.)E&7,
MY)/X7=_)J^PG:R$\`_LU?L5_%7Q?9^'_``SXHT+Q#KFH%A:V&G_$J_N+FX*H
M7;8B7A9L*K,<#@`FOK?X/?!O0/@)X`LO"_A>VN;'1+!I'BAGO9[QU,CEVS),
M[R'+,3RQQT&!7S[H?_!0/]D+PQJL5_IOC?X6Z=?6^?*N+:UCAECR"#AEC!&0
M2.#T->^_!/X^^#?VD/!K>(?`WB'3O$VB+<O9F\LF+1"9`-Z9('(W#\Z68RQ3
M2=15.7^]>U_FDOU!6Z6/&/\`@GI?W-_XV_:,6XNKJX%O\5M1BB\R5G$2"SLB
M$7)^502>!@<FOI@#H"/UKX/_`&7/VV_A/^S1\8?VB-$\>>/="\+ZM>_%#4+V
M&UOI&222$VMF@D&%(VED<?537N6@?\%2?V>_%&OV.EZ=\6/"=WJ&IW$=I:P1
MW#%YY9&"(@^7J6(`^M+'8'$RJ.<:<G&RU2=MEUL-25MS$_;YU&YL_C'^S,D%
MU<P)<?$R..=8I619D_LR_.U@#\RY`.#D9`KZ:#=!S7R1_P`%1?'^B_"KQE^S
MIXD\1:E;Z/H6B_$B.YO;VX)$5M'_`&9?C<Q`.!D@?C77_P##V;]F_`_XO!X0
MS_U\/_\`$T5,'7JX>C*E!R5GLF_M/L+F2;/H<DX.>!7Y:_LE>$OV6?%_PVU>
M^^+WCC1;/QT_BK7DO(=2^(%WIUQ'$NJ7*P`PK=(%'E!,849&#7Z,?!7X_>#O
MVD/!;^(O`WB'3O$^B)</9F\LG+Q"9`"Z9('(#+^=?"7["/[4?[-OPP^"&HZ-
M\1]?^'5CXMM?%GB%KJ'5K..2[1&U>[:/<S1DD%"I')X(^E=651JPH5E&,U).
M*:CI)?%OHW;OYA)JZ/8_@C^Q#^RM\9Y'U;P!=Q>+%T.[C,T^D^/=2OH[688D
M17V7;*#P#M;J.Q%>T?MJ_M$2?LJ?LQ>*_'5O8+JFHZ/;I'IUBS;5O+R>5(+>
M-B.0IFD3..<9KS7PM_P4L_95\!P31:)\2/AWH\=PX>5+%1;K*P&`6"(,G'&3
M7H?[:7P"F_:R_95\4>#M,OX;#4]7MXKK2+V0%HH+R"5+FVD;'.SS8TSCG:37
M/5]H\33>,4N2Z^.][75^WSL-6UL>:_#C_@F1X8\8Z1:Z]\=)+GXP?$._03ZE
M=:S<22:78RMRUO960800P(3M7Y"S`9)R<#7A_P"";WACX8>*M.U_X/ZQJWPB
MU2SNHY+NVTN62YT;5X`P\R"XT^5_).Y<A9(]CH2""<8.=\+?^"GW@BPTVWT+
MXQ7"_!OXC:>HAU72?$>;.UDF48:6TNF'D7%NYRR,CDX(R`:T;K_@IKX`\7>,
MM*\,_#!=0^,/B+4KN*&:#PM'Y]GI<!<"2YN;QL6\2(I+8+EF("@9.:NI_:?,
MTT^7_P`DM_Z3;MT%[IZ+^T%^REX(_:EM=)@\:Z9?ZC'HCR268MM6O-/,;2!0
MY)MY8R^0HX;..V,FOC[XJ_\`!/CX6>&_V_\`X1^"++2_$,/AGQ/X>U^^U.R_
MX2G5&%S-;&S\A]QN-Z[?-DX4@'=SG`K]#`<_6OE_XZ<_\%5O@'U_Y%+Q5_/3
MZG*<;7A*5.,VDHS:2;LGRMWMZA)+>QWOP*_84^&?[-GC27Q!X0T;5+#5)[5[
M)Y+C7M0OD,3,C$>7/,Z`Y1?F`R,=>363_P`%`/VA-7^"'P6@TKP<J7'Q+^(E
M\GACPA;'DB^N`0;EAVCMXA),QZ`1@'K7N[G8"20%'.3VKX+\/>#_`(E?M]?M
M1ZK\:_`?C/0_!_A3P'+=^$/!,VJ>'SK$>I(&"ZAJ4*&:()YDR&%)!DM'$1P"
M<Q@4\16=?%3TBKMR;LWT75ZO>W2X-65D=!^R[X/O_P#@G!^TWI/PEU37]9\0
M>!/BMIRWGA[5=6NGN);?Q!:PJ+^U9W8D"ZC47"+G`9)%45]J$9R3BOBG]I']
MA?\`:(^/OPY6PU3XV>#+Z]T2\AUS1FM_`_V&XMM1MF\RWDCG%TQB.\;2VT_(
M[`@@D5[_`/L7_M(Q_M4_L_:/XHFLVTK7H3)IOB'2W&)-(U2W8Q75LP/(VR*2
MN>J,I[U69TU5C'$J:D]I<M]^CU2W2L_->8XNVA\K?L/?L/\`PR_:4\"^-O%'
MCBRUO5M=D^('B6T,_P#PD^I6P$46ISI&@2*X5`%4`#`[5Z/\5_\`@F;\!_`G
MP[UK6X=0\3>`)=)M)+N/Q#:^-]3CETED4L)@9+ED.TC.&!!Z8YKSC]@S]@/X
M/_M%_#WQOXG\:^!]-U_79OB'XGMY+R::='=(]5N%1<(ZCA>.E1_MA?\`!,;X
M?_L\ZAX<^+G@+X9:9XDT?P/*9?%7@J:-[Z#6M-)S)=6\4K,#>6V/,13D2*K*
M1G&?8JXF,L9*DL1-:M)6]V_2-^;9[7M;OH0EI>Q],_\`!.GXH^*/C1^P_P##
M3Q3XQ,C^)-9T6*>[FDA\IKOEE2<KV,L823T^>BO2?A=X^T'XJ?#C1/$?A:\M
M-0\.:U91W6G7%L1Y,D#*"FT#I@<;>""""`1BBOE<0U*K*27+=O3MKM\C1'A_
M_!6#]D27]L_]B;Q1X6TV$3^)M-"ZUH*]"][;Y98A_P!=4,D7_;7/:OYNY8G1
MGCDCEAEC8HZ,"DD3`X((ZJP(QZ@BOZUP,$DYR:_'K_@N'_P2*U+2O$^L?&WX
M7:3/?Z=J):\\6:':1EY;27J^H0(.61NLJ`95LR#(+[?T3P_XCIX:3R_$RM&3
MO%O9/JOGI;S.;$4[^\CZ;_X(S?\`!4G3?VQ/A5I_@;Q;J45O\5?"]J(9TG<*
MWB*VC7"WD6?O2;0/-0<ALM]UAC[IV@X!&17\F7A[Q%?>&M:L=7TB_N].U+3Y
M5N;.]LYVAGMI%.5>.12"K#U!K]"_V7_^#CKXH_"G2;72OB)X>TWXD6=LH0:@
MDW]FZH5`P-[*K12GWV(3W)/-=/$?A]6=66(RVSB]7%NUGY-Z6\G:PJ>)5K2/
MV^%E$)_-$,?F'^+:-WYU+@`].!7Y@R?\'/GP]&E[U^%OCLWN/]2;JS$>?]_?
MG'_`:^</VI_^#B[XK_&32KK2/`&BZ=\,M.N04:^2;^T-6VD8.R1E6.(^ZHS#
MLP/-?+X/@/-JD^3V7(NK;5OPNW\C65>"ZGV5_P`%M/\`@J1IO[,/PLU+X9>#
M-4BN?B=XIM6M[AK>0,?#5G(N'GD(^[.ZDB)/O#/F'`5=WX7:?I\]]=6]G96\
MUU=7,B6]O;PJ7DGD8A4C4=2S,0`.Y(I^L:Q<ZSJ5WJ.HWES>WU[*T]S=7,K2
MS7$C'+.[L2S,3U)))K]9O^"'/_!(O4="U[2OC?\`%+2I;"XM`+CPEH-W'MFC
M8CC4+A#RC`']TC#<,[R`=F/U"C1P7"^6N4WS3?R<I=$NR7X;G*W*K,^[_P#@
MF?\`LFG]B_\`8S\(>";I8AKB0-J.MNG(>_N#YDPSW"$B,'NL:U[VJCG(R12C
M+9/2N0^/<C0_`WQDZ.T4B:'>L'4D,I%N_(QW%?AE>O/$XB56H_>F[M^;9W6L
MK(Z35M*MM<L9;2\MK>\MIUVO#-&)(W'H5/!'UKGO#7P,\$^#-5^W:/X/\+Z5
M?`[OM%GI5O!+GUW(@.?QKXU^#?[/$^O?!KPM?G]GJUUJ6\T:TG.HR?$*2W>^
M+0(WG%>J%R=V.V<=JZ?4/$]WJ_\`P2ZTLW&KWVH:IIFL6&F7LTTK--!/#KD4
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M\2OV@KO6(--\$_$O2K;2K>W3PQKNM3V3:))ND+3I'&DD;><"N6D0,/+`4XS5
MG]EG6;3X9_$7Q9X#C\`W7@GQ,ND1Z_'IMOXC?6-)N(=[PJ8=Q'V=C)P4\M-P
MP>0*J6$YJ/.IW=DVM-/O=]+[VL'-K:Q]$7.C:?),SRVEFTDIY9XU+,?Q')I5
MT#3XW5A96@93D$0J"#Z]*^7?V4?V??`_[4/P6TWQQX[@_P"$Y\9Z[YDFKSZC
M=2NVD70=@]E%"&"VRPD;`JA6^7)))S7:?$?P[H?@3]B/XH:9X8\1W^O:?IVB
M:Q%')/JW]HRZ:ZV\F;439+@1'@*[%EZ$]*FK0Y9^R4VVG9Z:=M'?]$.,KJY[
MI=V$-^H6>&*95.0)$#`'UYJ$>'M-'_+C9_\`?E?\*^4_VK-(N?%/P`^`NFPZ
M='KTNJ:UIL+:=<:C)8PZB#IEPQCDG0%E7C.<'E1Q79?LX_LI:5X=\6'6]:^&
M.A^#]6T>1)=+FT_Q3>:MYC%75RRR+&JX!`&0V=QZ8JGA8PH^T<VGKHDNC_Q)
M_<F)2;=K'T#;6<-E$8X8HH4/.U%"CZX%0'P]8.Y9K&S+-R285)/Z5\K^+/!?
MBW6_VV/B9XC\$:I-#XH\(Z3H<EKIEU<LNF:W!*ET9[.9>B%_+0I*!F-U!.5+
M"MGX7?&ZP^./[:7AO4M--]9/!X'U.VU/2;LF.YTF]CU"T62">+/RR*<@'HRD
M%25(-#P4TN>,K^ZF_*ZND_\`,.8^CGT#38E+-9604>L2`?RJ\N!P.@KY:^%7
MPN\.?M5?%?XFW7Q)1_$>L>&/$D^D67A^]N7%GHM@BH;>5+8,%9IU;S#,P);.
M`0%Q7K?P:^%OA'X0:OXCTCPIJ]T(T$,L^@MJIO(=%)5MK1Q.6>`2#)VYVG;E
M0.:RK4%'1R;DK/;36W6_Z:C3N=YK/A_3_$=MY&HV5G?P$Y,=Q"LJ?DP(I^E:
M/9Z#:""RM+:S@7D1P1+&@_``"O@S]D;]FJ?XE?"CPCJFI?"GP]KFGZH=UUKM
MSXUO8;R>(SL&F-LL94.%!P@?!P.1GCZ`_:>_9^GU3X4>#O"/@Z\T73].TG4D
M(\.ZIJ=Q:VOB&W2*3_0VF0F8X)$F/F!\OY@1717P4*=54'4ZV>BLK>DG]SMY
MDJ;:O8]\259.5(8'N#FF/;1R3K*8T,B9"L5!90>H![9KY!\)Z#:?LT?%WP?J
M6O\`P@T[P0-;U6/0K74O"WBN6XMGN+A62-+BS*Q>:A.3N*OL(#8XS7V&,'D<
MXKDQ6'5*2Y7=-;Z?HVOQ*C*XI&00>0:BMK>.TB6**-(HT&%5%"JOT`J6BN:Y
M05##:Q0%RD4:&1M[[5`W'U/J?>IJ*+@0P6T=LI6-$C#'<0J@`D]3QW-3444[
M@16]K%:0B*&)(HUZ(BA5'/H**EHH;`*"`001D&BBD!\#?MU?\$#_`(;?M0ZO
M?>)O!5R/AGXQO"TLYM+82Z5J,AR2TML"NQR>KQ%<]2K&OS=^-'_!"O\`:2^#
M][.+;P=:>-K"-B$O/#U_%/Y@]?)E,<H^FT_6OZ&G^Z:9DU];E/&^9X*"IJ2G
M%;*6MO1Z/\S&=",O(_F3'_!-_P#:"^U>3_PI7XE^9_V!)@O_`'UC;^M>N_!3
M_@A%^T?\8+R$WWA2P\#Z?*1ON_$&H1QM&/40PF24GV(7ZBOZ$>CX'`H;J1VK
MUL1XEYC*+4(1B^]G_F9QPT3X7_8._P""$OPR_9*U:Q\3>*)F^(_C>S(E@NK^
MW6/3]-D'.Z"VRP+@]))"[#@KL-?=.T8P!@4@/S-2CM]*^(S#,L3C:WM<5-RE
MY]/1;(Z(0459"U3UO1[7Q#I%WI]["EQ9WT+V\\3_`'98W4JRGV()%7**XF[:
ME'BT7_!/;X,Q1+&G@+252,!54/,%`'0`;^E=U)\#_"#_``XM_!Z^'M,B\,6C
M1-%ID4(BMXS%*LJ$*N.1(JMGN1DYKK\`=`*#T-;SQ=>=N:;=M5=O1DI)=#G/
MB-\+?#OQA\+R:-XGT73]<TR1A(;>[B$@5U^ZZGJKCLRD$=C7,_#;]DSX>?"+
MQ*NM:!X9MK?5TC,4=]<337ES`AZK'),[L@/0A2,BO1\X08XIU9QQ%2,73C)V
M[7T^X;2///B=^RWX!^,&OQZQX@\-65WK,48B748'DM+S8.B&:%DD*CL"V!5_
MX4?`/P?\$$O!X7T&UTN;46#7=P"\US=%?N^9-(6D<#)P&8@9.*[-ONFA/NBF
ML35<?9N3MVOI]P66YY9XW_8Q^&7Q&\3W>MZKX3M&U34#NO)[2XGLFO3ZS"%T
M$IQW<$FNITOX.>%M$^&\W@VR\/Z79>%KFUDLY=-MX!%;R12*5D4JN,[@3D]3
MDDG-=72*3DT2Q-5I1E)M=-=@Y5V.+^('P!\&_%7P=IOA[Q!X?LM4T;1WCDLK
M67<$MFC0QH5P000A('/0USGA?]B/X5^"_$^GZSI7@W3K/4M+G6YM9UEF)AD7
MHPRY&1[BO5U/RBD8\"G'%55"RDTNUW8++L8^F>!='T?QCJNOVMA;PZSK<4$%
M]=*#YERD(<1*WLN]\?[QK/M/@]X8T_XHW?C:WT/3X?%E]9C3[C4TBVW$\`*D
M(Y'W@"J\GG"@9P!7545/M):ZO:WR[#//?BG^RWX"^-&NPZIXC\-VMYJT$?E)
M?PRRVEWY?]PS0LCE?]DL1[5J_"SX)>$_@GHL]AX6T'3]%M[I_-G\A,R7+_WY
M)&R\C8[L2:ZQ3\HI30\35<?9N3MVOI]PK*]SQA/^"?7P:7A?`6DH"2<+),HR
M3D\!\=:Z75?V8/A]KGPSL?!U[X4TF\\.:42]E93QF06;%BQ>-R=Z-EF^96!Y
M/->@C[YH/WC]*TGBZ\K.4V[:K5Z!9=CS'P+^R!\.?AQXIMM;TOPU"=6L`1:W
M5Y=7%]):9&"8C.[^6<<93!QQ7IV.!@X%(_;BG5%2K.;YJDFWYNX));!1114#
/"BBB@`HHHH`****`/__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
